Telemedicine may fail if it is not adapted to patients
DOI:
https://doi.org/10.19230/jonnpr.2130Keywords:
Telemedicine, Asthma, Chronic obstructive pulmonary diseaseAbstract
Introduction: Asthma is one of the most prevalent chronic diseases of the respiratory system, assuming an important health problem in times of exacerbation and poor control of the disease. In most of the diagnosed cases, the habitual monitoring and knowledge of the disease by the patient helps to considerably reduce the number of seizures and the associated symptomatology. However, several factors can mask the correct control of asthma, such as the effect according to seasonality, the asymptomatic situation in inter-crisis periods or even pre-established medical monitoring patterns without knowing the patient's current situation. Telemedicine is a tool that allows to interact remotely with patients, offering the possibility of objectifying the control of the pathology and even modifying treatment guidelines. Today, where technological development is a reality, this possibility has ceased to be a utopia to become another option for medical monitoring.
Objective: To compare the degree of control between asthmatic patients with telematic follow-up and patients without telematic followup.
Method: We conducted a prospective, randomized, triple-blind study in a population of asthmatic patients, usually followed up in the Pneumology Clinics of the University Hospital Complex of Albacete, using a digital platform accessible through a connection to the network (computers / smartphones). ), which allow the patient to offer the doctor who follows him basic information on a daily basis about the control of his disease.
Results: 46 subjects participated (25 study group and 21 control group). The pharmacological completion has been higher than 95% in those who have used the system assiduously. The Peak flow of the study patients suffers an increase of 7% with respect to the initial values. More than 50% of patients had increased their treatment before entering the study, since their inclusion in the study none had to increase treatment. Even 25% have decreased the treatment dose. They have improved their level according to the base treatment in 32% of the patients. At three months only 26% of the patients in the study group and 10% of the control group complied with the data entry even after the notices that were issued from the portal, so despite the good results it was decided to suspend the study , warning patients.
Conclusions: The medium-long term monitoring of the programs through telemedicine is difficult. It has to be an adaptation of telemedicine to patients and vice versa.
Downloads
References
American Thoracic Society. Standards for the diagnosis and care in patients with chronic obstructive pulmonary disease and asthma. Am Rev Respir Dis 1987; 136: 225-244.
Barnes PJ. New Concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. J Allergy Clin Inmunol 1988; 83: 1013.
Barnes PJ, Johnsson B, Klim JB. The cost of asthma. Eur Respir J 1996; 9: 636-642.
Barron WM, Leff AR. Asthma in pregnancy. Am Rev Respir Dis 1993; 147: 510-511.
Boulet L, Chapman KR. Asthma education. Chest 1994; 106: 184-196.
Barry PW, O'Callaghan C. Inhalation drugs delivery from seven different space devices. Thorax 1996; 51: 835-840.
British Thoracic Society. Guidelines on the management of asthma. Thorax 1993; 48 (Supl): 1-24.
Campo A, Galdiz JB, Pascal I, Sobradillo V. Asma en urgencias: ¿podemos disminuir la tasa de reingresos tras el alta? Arch Bronconeumol 1999; 35: 529-534.
Cimas JE, Arce ME, González ME, López Viña A. Estudio de los factores relacionados con la morbilidad del asma. Arch Bronconeumol 1997; 33: 389-394.
De Diego A, Casan P, Duce F, Gáldiz JB, López Viña, Plaza V. Recomendaciones para el tratamiento de la agudización asmática. Arch Bronconeumol 1996; 32: 1-7.
Fanta CH, Rossing TH, McFadden ER. Glucocorticoids in acute asthma: a clinical controlled trial. Am J Med 1983; 74: 845-851.
Abramson MJ, Bailey MJ, Couper FJ, Driver JS, Drummer OH, Forbes AB, et al. Are Asthma Medications and management Related to Deaths from asthma?. Am J Respir Crit Care Med 2001; 163: 12-18.
Fraj Lázaro J, Duce Gracia F. Medidas de evitación alérgica en el asma. Arch Bronconeumol 1999; 35: 345-356.
Global initiative for asthma. Global strategy for asthma management and prevention. National Institute on Health. National Heart, Lung and Blood Institute. NIH Publicación n.o 95-3659. Enero de 1995.
Grupo de trabajo de la SEPAR. Normativa sobre diagnóstico y tratamiento del asma aguda y crónica. Barcelona: Ediciones Doyma, S.A., 1996.
Grupo de trabajo de la SEPAR. Normativa para la espirometría forzada. Arch Bronconeumol 1989; 25: 132-142.
International consensus report on diagnosis and treatment of asthma. National Institute of Health. Publicación n.o 92-3091. Marzo de 1992. Eur Respir J 1992; 5: 601-641.
Jones et al. Salmeterol xinofoate in the treatment of mild to moderate asthma in primare care. Thorax 1994; 49:971-975.
Lederle FA, Pluhar RE. Tapering of corticosteroid therapy following exacerbation of asthma. A randomized double-blind placebo controlled trial. Arch Intern Med 1987; 147: 2201-2203.
Carmen Rodríguez de Castro, Alberto J. Ordóñez, Pedro Navarrete, F. Javier Gómez Jiménez y Manuel J. Castillo. Aplicación de la telemedicina al control de enfermedades crónicas: telecontrol de pacientes con enfermedad pulmonar obstructiva crónica. Med Clin (Barc) 2002;119(8):301-3
L. Otero, A. López-Viña, L. Sánchez-Agudo, M. Carmona, J.A. Fragua, P. García-Sagredo, M.A. González, A. Muñoz, M. Pascual, C.H. Salvador. El futuro de los cuidados “asma y telemedicina”. REV PATOL RESPIR 2005;8(SUPL. 1): 62-63.
Van der Palen J, Klein JJ, Rovers MM. Compliance with inhaled medication and self-treatment guidelines following a self-management programme in adult asthmatics. Eur Respir J 1997; 10:652-657.
Steel S, Lock S, Johnson N, Martínez Y, Marquilles E, Bayford R. A feasibility study of remote monitoring of asthmatic patients. Journal of Telemedicine and Telecare 2002, vol 8; n5: 297-301.
Francisco Jódar-Sánchez, Francisco Ortega, Carlos Parra, Cristina Gómez-Suárez, Ana Jordán, Pablo Pérez, Patricia Bonachela, Sandra Leal, and Emilia Barrot Implementation of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long-term oxygen therapy. J Telemed Telecare. 2013;vol. 19, 1: pp. 11-17.
Josep Comín-Colet, Cristina Enjuanes, José M Verdú-Rotellar, Anna Linas, Pilar Ruiz-Rodriguez, Gina González-Robledo, Núria Farré, Pedro Moliner-Borja, Sonia Ruiz-Bustillo, and Jordi Bruguera. Impact on clinical events and healthcare costs of adding telemedicine to multidisciplinary disease management programmes for heart failure: Results of a randomized controlled trial. J Telemed Telecare , 2015
Pascual M, Muñoz A, González MA, Fragua JA, García-Sagredo P, Otero L, Márquez-Montes J, Luque M, Monteagudo JL, Salvador CH. Airmed-Cardio 2: Descripción del Sistema. CASEIB 2003; 227:230.
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
